File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B

TitleHepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B
Authors
Issue Date2010
PublisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=7
Citation
Expert Review Of Anti-Infective Therapy, 2010, v. 8 n. 6, p. 717-726 How to Cite?
AbstractDespite universal vaccination, chronic hepatitis B (CHB) continues to be a major health burden worldwide, with an estimated 350-400 million people infected with the virus. Over the past decade, rapid progress has been made with regards to antiviral therapy for CHB, from conventional interferon to pegylated interferon, and with the earliest oral agent lamivudine to the current, more potent drugs such as entecavir and tenofovir. There have also been new developments in the diagnostic and monitoring tools for CHB. Qualitative hepatitis B surface antigen (HBsAg) testing has been used to diagnose patients infected with CHB. More recently, quantitative HBsAg titers have been used to predict treatment outcome when measured at baseline or early into treatment. The progress on the use of hepatitis B virus (HBV) DNA levels has been more rapid. Serum HBV DNA levels have been shown to be important in the natural history of CHB infection, with higher levels being significantly associated with the development of cirrhosis and hepatocellular carcinoma. For patients receiving antiviral therapy, the baseline and early on-treatment HBV DNA levels are important in determining treatment outcomes. Monitoring of HBV DNA levels during therapy will allow for early detection of drug resistance. The end-of-treatment and post-treatment HBV DNA levels have been demonstrated to be important indicators of treatment success and relapse, respectively. With newer and more powerful antiviral agents, and with the development of quantitative assays that are highly sensitive, further studies are needed to optimize the use of these tools and agents in the modern management of CHB. © 2010 Expert Reviews Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/163319
ISSN
2015 Impact Factor: 3.542
2015 SCImago Journal Rankings: 1.415
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFung, Jen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, MFen_US
dc.date.accessioned2012-09-05T05:29:59Z-
dc.date.available2012-09-05T05:29:59Z-
dc.date.issued2010en_US
dc.identifier.citationExpert Review Of Anti-Infective Therapy, 2010, v. 8 n. 6, p. 717-726en_US
dc.identifier.issn1478-7210en_US
dc.identifier.urihttp://hdl.handle.net/10722/163319-
dc.description.abstractDespite universal vaccination, chronic hepatitis B (CHB) continues to be a major health burden worldwide, with an estimated 350-400 million people infected with the virus. Over the past decade, rapid progress has been made with regards to antiviral therapy for CHB, from conventional interferon to pegylated interferon, and with the earliest oral agent lamivudine to the current, more potent drugs such as entecavir and tenofovir. There have also been new developments in the diagnostic and monitoring tools for CHB. Qualitative hepatitis B surface antigen (HBsAg) testing has been used to diagnose patients infected with CHB. More recently, quantitative HBsAg titers have been used to predict treatment outcome when measured at baseline or early into treatment. The progress on the use of hepatitis B virus (HBV) DNA levels has been more rapid. Serum HBV DNA levels have been shown to be important in the natural history of CHB infection, with higher levels being significantly associated with the development of cirrhosis and hepatocellular carcinoma. For patients receiving antiviral therapy, the baseline and early on-treatment HBV DNA levels are important in determining treatment outcomes. Monitoring of HBV DNA levels during therapy will allow for early detection of drug resistance. The end-of-treatment and post-treatment HBV DNA levels have been demonstrated to be important indicators of treatment success and relapse, respectively. With newer and more powerful antiviral agents, and with the development of quantitative assays that are highly sensitive, further studies are needed to optimize the use of these tools and agents in the modern management of CHB. © 2010 Expert Reviews Ltd.en_US
dc.languageengen_US
dc.publisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=7en_US
dc.relation.ispartofExpert Review of Anti-Infective Therapyen_US
dc.subject.meshAntiviral Agents - Therapeutic Useen_US
dc.subject.meshDna, Viral - Blooden_US
dc.subject.meshHepatitis B Surface Antigens - Blood - Immunologyen_US
dc.subject.meshHepatitis B Virus - Drug Effects - Genetics - Isolation & Purificationen_US
dc.subject.meshHepatitis B, Chronic - Diagnosis - Drug Therapy - Immunology - Virologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver - Virologyen_US
dc.titleHepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailFung, J:jfung@sicklehut.comen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1586/eri.10.45en_US
dc.identifier.pmid20521898en_US
dc.identifier.scopuseid_2-s2.0-77953281786en_US
dc.identifier.hkuros174088-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77953281786&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume8en_US
dc.identifier.issue6en_US
dc.identifier.spage717en_US
dc.identifier.epage726en_US
dc.identifier.isiWOS:000279408800015-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridFung, J=23091109300en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.citeulike7280106-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats